CASIA OpenIR
Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging
Liu, Shengnan1,2; Du, Yang2,3,4; Ma, He1; Liang, Qian2,3,4; Zhu, Xu5; Tian, Jie2,3,4,6,7
Source PublicationCANCER LETTERS
ISSN0304-3835
2019
Volume453Pages:74-83
Corresponding AuthorMa, He(mahe@bmie.neu.edu.cn) ; Zhu, Xu(drzhuxu@163.com) ; Tian, Jie(jie.tian@ia.ac.cn)
AbstractSorafenib has been used as a clinical targeted therapy for hepatocellular carcinoma (HCC) for more than a decade. In 2017, regorafenib was approved for HCC treatment and has since been reported to prolong the survival of advanced HCC patients after treatment failure with sorafenib. However, there has been no direct systematic comparison of the therapeutic effects of regorafenib and sorafenib against HCC. In this study, we comprehensively compared the therapeutic effects of sorafenib and regorafenib against HCC in vitro and in vivo using multimodality molecular imaging, which can show molecular and cellular differences at early stages. The side effects of sorafenib and regorafenib were also systematically evaluated. The data showed that compared with sorafenib treatment, regorafenib exerted stronger antitumor and antiangiogenic effects and significantly increased the survival rate of HCC mice. Sorafenib but not regorafenib treatment caused body weight loss and liver and kidney dysfunction, while regorafenib but not sorafenib treatment caused hypertension. Our study may provide an experimental basis for the guidance of clinical HCC targeted treatment with regorafenib and sorafenib.
KeywordHepatocellular carcinoma Regorafenib Sorafenib Molecular imaging Therapeutic effects
DOI10.1016/j.canlet.2019.03.037
WOS KeywordBAY 73-4506 ; APOPTOSIS ; THERAPY ; CANCER ; TUMOR
Indexed BySCI
Language英语
Funding ProjectNational Key Research and Development Plan of China[2017YFA0205200] ; National Natural Science Foundation of China[81871514] ; National Natural Science Foundation of China[81470083] ; National Natural Science Foundation of China[81227901] ; Strategic Priority Research Program from Chinese Academy of Sciences[XDB02060010] ; International Innovation Team of CAS[20140491524] ; Beijing Municipal Science and Technology Commission[Z161100002616022]
Funding OrganizationNational Key Research and Development Plan of China ; National Natural Science Foundation of China ; Strategic Priority Research Program from Chinese Academy of Sciences ; International Innovation Team of CAS ; Beijing Municipal Science and Technology Commission
WOS Research AreaOncology
WOS SubjectOncology
WOS IDWOS:000467511100007
PublisherELSEVIER IRELAND LTD
Citation statistics
Cited Times:1[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Identifierhttp://ir.ia.ac.cn/handle/173211/24586
Collection中国科学院自动化研究所
Corresponding AuthorMa, He; Zhu, Xu; Tian, Jie
Affiliation1.Northeastern Univ, Sinodutch Biomed & Informat Engn Sch, Shenyang, Liaoning, Peoples R China
2.Chinese Acad Sci, Inst Automat, State Key Lab Management & Control Complex Syst, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China
3.Beijing Key Lab Mol Imaging, Beijing 100190, Peoples R China
4.Univ Chinese Acad Sci, Beijing 100080, Peoples R China
5.Peking Univ, Sch Oncol, Key Lab Carcinogenesis & Translat Res, Dept Intervent Therapy,Minist Educ Beijing, 52 Fucheng Rd, Beijing 100142, Peoples R China
6.Beihang Univ, Sch Med, Beijing Adv Innovat Ctr Big Data Based Precis Med, Beijing 100191, Peoples R China
7.Xidian Univ, Sch Life Sci & Technol, Minist Educ, Engn Res Ctr Mol & Neuro Imaging, Xian 710126, Shaanxi, Peoples R China
First Author AffilicationInstitute of Automation, Chinese Academy of Sciences
Corresponding Author AffilicationInstitute of Automation, Chinese Academy of Sciences;  Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing 100190, Peoples R China
Recommended Citation
GB/T 7714
Liu, Shengnan,Du, Yang,Ma, He,et al. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging[J]. CANCER LETTERS,2019,453:74-83.
APA Liu, Shengnan,Du, Yang,Ma, He,Liang, Qian,Zhu, Xu,&Tian, Jie.(2019).Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.CANCER LETTERS,453,74-83.
MLA Liu, Shengnan,et al."Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging".CANCER LETTERS 453(2019):74-83.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Liu, Shengnan]'s Articles
[Du, Yang]'s Articles
[Ma, He]'s Articles
Baidu academic
Similar articles in Baidu academic
[Liu, Shengnan]'s Articles
[Du, Yang]'s Articles
[Ma, He]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Liu, Shengnan]'s Articles
[Du, Yang]'s Articles
[Ma, He]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.